Trial · NCT07882901
Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment
NCT07882901, Phase 2, Not yet recruiting, Los Angeles Brain Science Project
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment. Trials, record NCT07882901. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882901
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment
- NCT number
- NCT07882901
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 44 participants, estimated
- Lead sponsor
- Los Angeles Brain Science Project
- Conditions
- Mild Cognitive Impairment (MCI)
- Interventions
- Tadalafil 5 mg
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Compliance (%) with tadalafil | From beginning to the end of treatment at four weeks | Assessed as the value equal to 100 x (number of dispensed tablets - returned tablets) / (planned days on trial medication) |
| Secondary | Cerebrovascular Reactivity to Hypercapnia | Baseline (pre-) and post-intervention at 4 weeks | Measured using transcranial doppler ultrasonography (TCD) of the bilateral middle cerebral arteries and breath-holding test (BHT) techniques |
| Secondary | Resting Heart Rate | Resting heart rate measured at baseline (pre-) and post-intervention at 4 weeks | Resting heart rate (bpm) measured using the OMRON BP7000 Evolv Upper Arm monitor |
| Secondary | Blood Pressure | Baseline, twice daily throughout the study (i.e. 4 weeks), and post-intervention at 4 weeks | Blood pressure (mmHg) measured using the OMRON BP7000 Evolv Upper Arm monitor |
| Secondary | Neurocognitive Testing | Baseline (pre-) and post-intervention at 4 weeks | 1. Fatigue and Altered Cognition Scale (FACs) - 20 item questionnaire equally divided into 10 categories designed to determine altered cognition and another 10 categories to assess central fatigue within the previous two weeks. Each item operates under a 0 (not at all) - 100 (extremely), with higher scores indicating feeling more aligned with the statement or symptom(s). 2. Creyos Cognitive Assessment - brief assessment of attention, mental rotation, deductive and verbal reasoning, and visuospatial and episodic memory. Each domain is graded on a sex- and age-specific standardized scale with no fixed minimum or maximum value. Distributions operate with a mean score = 100 and standard deviation = 15. Demographic-specific scales are used to describe the results, including scores ≤ 87 described as "Below average," scores ≥ 113 described as "Above average," and all scores between these two bounds described as "Average." |
| Secondary | Adverse Events | During the intervention period | Any and all adverse side-effects experienced while taking tadalafil will be documented using a written paper-based log. Summarization of adverse events, characterized by frequency and severity, will be facilitated |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Mental Rotation | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882901
GET https://conductscience.org/api/trials/v1/NCT07882901/registered